近視性脈絡膜新生血管に対するベバシズマブ硝子体内投与の2年経過

Two-year outcome of intravitreal bevacizumab for myopic choroidal neovascularization

要約　目的：近視性脈絡膜新生血管（CNV）に対するベバシズマブの硝子体内投与後2年間の結果の報告。症例：近視性CNV 37例38眼を対象とした。女性31例，男性6例で，年齢は39～80歳，平均60歳であった。屈折は－6.30～－20.50D，平均－11.50Dであった。視力はlogMARとして評価した。結果：投与前の平均視力は0.61±0.42で，3か月後には0.39±0.31，6か月後には0.35±0.27，2年後には0.45±0.36と，いずれも有意に改善した（p＜0.05）2年間の平均投与回数は2.1±1.4回であった。重回帰分析では，治療前視力，発症年齢，CNVの位置が視力の転帰に関係した。結論：近視性CNVに対するベバシズマブの硝子体内投与は，術後2年間にわたり有意な視力改善を示した。

Abstract.　Purpose：To report the outcome during 2 years after intravitreal injection of bevacizumab for choroidal neovascularization in myopic eyes. Cases：This retrospective study was made on 38 eyes of 37 patients who received intravitreal injection of bevacizumab for myopic choroidal neovascularization. The series comprised 31 females and 6 males. The age ranged from 39 to 80 years, average 60 years. Refraction ranged from －6.3 to －20.5 diopters, average －11.5 diopters. Visual acuity was evaluated in terms of logMAR. Results：Visual acuity averaged 0.61±0.42 before treatment. It averaged 0.39±0.31 after 3 months, 0.35±0.27 after 6 months, and 0.45±0.36 after 2 years. All the values were significant when compared with the value before treatment（p＜0.05）. The treatment was repeated 2.1±1.4 times when averaged for each eye during the period of 2 years. Multiple regression analysis showed visual acuity before treatment, age of patient and location of CNV as significant factors related with the visual outcome. Conclusion：Intravitreal injection of bevacizumab resulted in significantly improved visual acuity in eyes with myopic CNV.